hassan inanloo

Considering the importance of understanding COVID-19 prevalence and vaccine effectiveness in individuals dealing with bladder or prostate cancer, as well as the plausible adverse repercussions of immunization, this study was undertaken to assess the prevalence and vaccination rates of COVID-19 in this group of patient. Furthermore, the investigation seeks to evaluate potential adverse effects and the efficacy of vaccines in patients diagnosed with prostate and bladder cancer. In this cross-sectional study conducted from 2020 to 2022, we systematically extracted clinical and demographic information, COVID-19 diagnoses, clinical symptoms, and paraclinical data from the bladder and prostate cancer registry at our institution. Our analysis encompassed assessing the frequency of COVID-19 infections, vaccination rates, and the occurrence of adverse effects associated with vaccination within this specific cohort. Among the 249 enrolled patients, COVID-19 infection was confirmed in 19.4% of bladder cancer patients and 16.6% of prostate cancer patients. A substantial majority, 81% (202 patients), had received vaccination, with the Sinopharm vaccine being the preferred choice for the majority (90%).  The study's outcomes reveal a vaccine efficacy of 82% in individuals with bladder cancer, while displaying a higher efficacy of 96% among patients with prostate cancer. This study provides evidence supporting the efficacy of the SARS-CoV-2 vaccine in reducing COVID-19-associated complications and mortality, as well as its high efficacy in patients with prostate and bladder cancer.

Renal cell carcinoma (RCC) is uncommon during pregnancy. Accurate and timely diagnosis and careful preoperative planning are essential to optimize the patient outcomes. A 27-year-old pregnant woman presented with a large mass in left kidney and inferior vena cava (IVC) tumor thrombus, diagnosed at 33 weeks gestation. She was evaluated with an initial impression of pyelonephritis at other institutions and referred to our center after a delay of more than 3 weeks. RCC with IVC tumor thrombus has the potential to increase the likelihood of thromboembolic events including pulmonary embolism during pregnancy. Furthermore, simultaneous radical nephrectomy with IVC thrombectomy and Cesarean section (CS) is challenging and might be associated with significant intraoperative blood loss. After consultation with an obstetrician and cardiac surgery team, our patient underwent CS and simultaneous left radical nephrectomy with IVC thrombectomy at 34 weeks gestation. The postoperative course was uneventful and histologic analysis revealed pT3bN0M0 papillary RCC.